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Background: In boron neutron capture therapy (BNCT), positron emission tomography (PET) with 4-borono-2-18F-fluoro-
phenylalanine (FBPA) is the only method to estimate an accumulation of 10B to target tumor and surrounding normal
tissue after administering 10B carrier of L-paraboronophenylalanine and to search the indication of BNCT for
individual patient. Absolute concentration of 10B in tumor has been estimated by multiplying 10B concentration in
blood during BNCT by tumor to blood radioactivity (T/B) ratio derived from FBPA PET. However, the method to
measure blood radioactivity either by blood sampling or image data has not been standardized. We compared
image-derived blood radioactivity of FBPA with blood sampling data and studied appropriate timing and location
for measuring image-derived blood counts.
Methods: We obtained 7 repeated whole-body PET scans in five healthy subjects. Arterialized venous blood
samples were obtained from the antecubital vein, heated in a heating blanket. Time-activity curves (TACs) of
image-derived blood radioactivity were obtained using volumes of interest (VOIs) over ascending aorta, aortic arch,
pulmonary artery, left and right ventricles, inferior vena cava, and abdominal aorta. Image-derived blood
radioactivity was compared with those measured by blood sampling data in each location.
Results: Both the TACs of blood sampling radioactivity in each subject, and the TACs of image-derived blood
radioactivity showed a peak within 5 min after the tracer injection, and promptly decreased soon thereafter. Linear
relationship was found between blood sampling radioactivity and image-derived blood radioactivity in all the VOIs
at any timing of data sampling (p < 0.001). Image-derived radioactivity measured in the left and right ventricles
30 min after injection showed high correlation with blood radioactivity. Image-derived blood radioactivity was
lower than blood sampling radioactivity data by 20 %. Reduction of blood radioactivity of FBPA in left ventricle
after 30 min of FBPA injection was minimal.
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Conclusion: We conclude that the image-derived T/B ratio can be reliably used by setting the VOI on the left
ventricle at 30 min after FBPA administration and correcting for underestimation due to partial volume effect and
reduction of FBPA blood radioactivity.
Keywords: FBPA, PET, BNCT, T/B ratioBackground
Boron neutron capture therapy (BNCT) requires selective
delivery of 10B-containing drug to the tumor and irradiation
of the tumor with neutrons. Nuclear reaction yields high-
linear-energy-transfer α particles and recoiling 7Li nuclei in
the body [1, 2]. BNCT was effective in patients with inoper-
able, locally advanced brain tumors, head and neck cancers
and melanomas, even in those with tumor recurrence at
previously irradiated sites [3–5]. Successful application of
BNCT requires selective delivery of 10B to the tumor [1, 6].
In the BNCT practice, the 10B carrier used has been L-
paraboronophenylalanine labeled with 10B and conjugated
with fructose (BPA-fr) [7–9]. We previously reported that
4-borono-2-18F-fluoro-phenylalanine (FBPA) PET could
predict BPA-fr accumulation in the tumors transplanted to
rats [9]. Imahori et al. compared the 10B accumulation in
tumors estimated by the rate constants measured by means
of FBPA PET with that in surgically resected specimens of
high-grade gliomas using the prompt gamma method and
showed similar concentration of 10B in the tumor [10].
In the current BNCT, FBPA PET has been performed
to predict the accumulation of 10B in the tumors and
normal tissues [6, 8, 10–17]. Absolute concentration of
10B in the tumor has been estimated by multiplying 10B
concentration in the blood during neutron irradiation by
tumor-to-blood radioactivity (T/B) ratio derived from
FBPA PET. Although blood radioactivity in T/B ratio
has been measured by taking venous blood samples dur-
ing FBPA PET, the method to measure blood radioactiv-
ity either by blood sampling or image data has not been
standardized yet [4, 10, 12–14, 18]. We compared
image-derived blood radioactivity of FBPA with blood
sampling data and studied appropriate timing and loca-
tion for measuring image-derived blood counts in order
to estimate T/B ratio in the tumor.Methods
Subjects
This study was performed with the approval of the insti-
tutional ethics committee for clinical research of Osaka
University. Written informed consent was obtained from
each subject, after they were provided a detailed explan-
ation about the procedures of the study.
A total of 5 healthy volunteers (three males and two
females) participated in the present study after theyreceived a detailed explanation about the radiotracer
drug, the purpose and contents of the study. The mean
age of the 5 healthy volunteers was 34 years (range, 21
to 56), and the mean height and weight were 167 cm
(range, 160 to 174 cm) and 61 kg (range, 48 to 66 kg),
and the mean body mass index were 21.7 ± 1.8 (range,
18.8 to 24.5), respectively. None of the healthy volun-
teers had any prior history of any major medical illness.Preparation of radiotracers
FBPA was prepared by a previously described method,
with several modifications [7, 9, 19]. The F-1 synthesizer
(Sumitomo Heavy Industries, Tokyo, Japan) was used.
18F-acetylhypofluorite in Ne was bubbled at a flow rate
of 600 mL/min at room temperature into 5 mL of tri-
fluoroacetic acid containing 30 mg of 4-borono-L-
phenylalanine (Matrix SCIENTIFIC, COLUBIA, SC,
USA). Trifluoroacetic acid was removed by passing N2
under reduced pressure at a flow rate of 200 mL/min.
As in previous studies, the residue was also dissolved in
3 mL of water containing 0.1 % acetic acid, and the solu-
tion was applied to a high-performance liquid chroma-
tography column, YMC-Pack ODS-A S-5 (20 × 150 mm;
YMC, Kyoto, Japan), with water for injection containing
0.1 % acetic acid as the mobile phase, flow rate of
10 mL/min, ultraviolet detection at 280 nm, and a radio-
activity detector. The FBPA fraction (retention time = 19
to 21 min) was collected by adding 25 % ascorbic acid
injection and 10 % sodium chloride injection. The spe-
cific activity of FBPA was 49.7 ± 17.3 GBq/mmol as de-
termined by HPLC. The radiochemical purity of FBPA
was >98 %.PET image acquisition
All the healthy volunteers were instructed to fast for at least
4 h before the radiotracer injection [20, 21]. Before injecting
each radiotracer, the volunteers were asked to void their
bladders. Whole-body PET scans were performed using
Eminence SOPHIA SET-3000 BCT/X (Shimadzu Co,
Kyoto, Japan) in the three-dimensional acquisition mode.
Transmission data using a rotating 137Cs point source for
attenuation correction were acquired. The amount of
injected activity was measured in a dose calibrator (196 ±
16 MBq). Whole-body emission scans were initiated simul-
taneously with injection of the radiotracer into the
Fig. 1 Time–activity curves (TACs). TAC of blood sampling radioactivity in 5 healthy subjects (a) and TAC of PET image-derived blood radioactivity:
average values from 5 healthy subjects (b). Both the TACs showed a peak within five min after the FBPA injection, gradually approaching a constant
level at 20 min after the injection
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whole-body PET scans from the parietal crown to the groin
were performed in each of the five healthy volunteers. The
data consisted of seven scans with an acquisition time of
455 sec, and an interval between scans of 45 sec. Radio-
activity decay during the PET scan was corrected for the
FBPA injection time. All the images were reconstructed
using Dynamic Row-Action Maximum Likelihood Algo-
rithm (DRAMA) with an image matrix of 128 × 128, result-
ing in a voxel size of 4.0 × 4.0 × 3.25 mm3 [21]. The axial
field of view was 26 cm. After the PET scanning, whole-
body CT (80 kV, 135 mAs) was performed for image
fusion.
Time-activity curves (TACs) of blood sampling
radioactivity
Before and during the PET study, nine arterialized venous
blood samplings were obtained: at background, 30 sec, and
1, 3, 5, 10, 20, 30 and 50 min after the tracer injection from
the antecubital vein contralateral to the intravenous FBPA
injection side, heated in a heating blanket. The radioactivityFig. 2 Time-course of the PET image-derived blood radioactivity. Represen
healthy woman after injection of FBPA. High accumulation in the left ventr
soon thereafter and gradually approach a constant level at 20 min later aft(cps/g) of the whole blood was measured in a cross-
calibrated well-type scintillation counter (Shimadzu Co,
Kyoto, Japan), and fixed in attenuation correction to the
FBPA injection time.
TACs of PET image-derived blood radioactivity
The radioactivity in various blood pools was obtained
from reconstructed PET images by averaging the activities
in each blood pool, since the radioactivity distribution
within a blood pool can be considered to be uniform [22].
TACs of the image-derived blood radioactivity were ob-
tained using volumes of interest (VOIs) over the ascend-
ing aorta, aortic arch, pulmonary artery, left and right
ventricles, inferior vena cava and abdominal aorta. Spher-
ical VOIs with a diameter of 10 mm were set on these
blood pools of the PET images referring to the individual
CT images. VOIs were drawn on 3 cross-sections of the
tomographic images. Data were obtained for each of the
organs using PMOD software, ver.3.6. TACs were created
using the average values of five VOIs consisting of regions
of interest drawn over each blood-pool area.tative decay-corrected axial images of the left ventricle in a 56-year-old
icle was observed soon after the FBPA injection, to promptly decrease
er the tracer injection
1. Ascending aorta
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
2. Aortic arch
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
3. Pulmonary artery 
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
4. Left ventricle
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
5. Right ventricle
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
6. Inferior vena cava
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
7. Abdominal aorta
 ( BS 3min, PET 3.8min )        ( BS 20min, PET 20.5min ) ( BS 30min, PET 28.8min ) ( BS 50min, PET 53.8min )
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Fig. 3 (See legend on next page.)
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Fig. 3 Correlation between blood sampling radioactivity and image-derived radioactivity in each blood pool. The blood samplings radioactivity
(BS) at 3, 20, 30 and 50 min after the tracer injection and the image-derived blood radioactivity (PET) at each site (ascending aorta, aortic arch,
pulmonary artery, left and right ventricle, inferior vena cava and abdominal aorta) in mid-scan time at 3.8, 20.5, 28.8 and 53 min after the injection
were compared. BS is plotted on the horizontal axis, and PET is plotted on the vertical axis. Both units are in cps/g. A linear relationship was found
between blood sampling radioactivity and PET image-derived radioactivity in each blood pool (p < 0.001). Strong correlations were observed
between these parameters at 20 min after FBPA administration. The image-derived radioactivity measured in the left ventricle and right ventricle
30 min after injection showed high correlation (0.97 and 0.99, respectively), slope close to be 1.0 (0.96 and 0.95, respectively), and intercept (-161
and -149) with blood radioactivity
Isohashi et al. EJNMMI Research  (2016) 6:75 Page 5 of 8FBPA metabolite analysis
The proportion of 18F radioactivity in the plasma present
as FBPA was measured in 5 healthy subjects. Blood sam-
ples were collected at 20 min and 50 min after the FBPA
injection from the antecubital vein contralateral to the
intravenous FBPA injection side. Radiochemical purity
was analyzed by HPLC [10].Data analysis
We verified whether the image-derived blood radioactivity
was correlated with the blood sampling radioactivity in
the healthy subjects. TACs of the blood sampling radio-
activity were compared with those of the image-derived
blood radioactivity. The TAC of the image-derived radio-
activity within each blood pool was calculated as the aver-
age of five radioactivities (cps/g), respectively. The blood
sampling radioactivity at 3, 20, 30 and 50 min after the
tracer injection and the image-derived blood radioactivity
at each VOI (ascending aorta, aortic arch, pulmonary ar-
tery, left and right ventricles, inferior vena cava, and ab-
dominal aorta) in mid-scan time at 3.8, 20.5, 28.8 and
53 min after the tracer injection were compared.
The magnitude of underestimation of blood radio-
activity counts was examined. The timing of the minimal
reduction of image-derived blood FBPA radioactivity
was examined from TAC, and reduction of blood radio-
activity of FBPA in each blood pool was calculated and
compared, respectively.Statistical analysis
The relationships between the blood sampling radio-
activity levels and the radioactivity level within each
blood pools on the PET images were analyzed by with
linear regression and Spearman’s correlation tests. TheTable 1 Compaison of the proportion of blood sampling radioactiv
Ascending aorta Aortic arch Pulmonary arte
PET 3.8 min/BS 3 min (%) 71 ± 24 65 ± 28 76 ± 32
PET 20.5 min/BS 20 min (%) 83 ± 6 81 ± 4 88 ± 7
PET 28.8 min/BS 30 min (%) 84 ± 7 81 ± 7 86 ± 10
PET 53.8 min/BS 50 min (%) 66 ± 5 71 ± 6 68 ± 15
Data are mean ± SDcorrelation coefficient was also estimated as a statistic to
express the comparability of these values.
The proportion of blood sampling radioactivity and
image-derived radioactivity and that of reduction rate
was described as the mean ± SD. Mean values were com-
pared using a one-way analysis of variance. In all the
statistical analyses, significance was defined as a P value
of less than 0.05. All the statistical analyses were per-
formed with StatMate IV (ATMS Co., Ltd., Tokyo,
Japan).
Results
The TACs of the blood sampling radioactivity showed a
peak within five min after injection in each subject,
promptly decreasing thereafter (Fig. 1a). The FBPA
radioactivity gradually approached a constant level at
20 min after the injection. The peak of the image-
derived blood radioactivity was found in the first image
in all blood pool structures in each subject, and grad-
ually approaching a constant level at 20 min after the in-
jection (Fig. 1b). Representative PET tomographic
images of the blood pools are shown in Fig. 2.
A linear relationship was found between the blood
sampling radioactivity and image-derived radioactivity in
each VOI (Spearman’s, p < 0.001) (Fig. 3-1, 3-2). The
image-derived radioactivity measured in the left ventricle
and right ventricle at 30 min after injection showed high
correlation (0.97 and 0.99, respectively), slope close to
be 1.0 (0.96 and 0.95, respectively), and intercept (-161
and -149) with blood radioactivity.
Table 1 summarized a proportion of image-derived
radioactivity to blood sampling radioactivity in each
sampling time. Mean proportion of image derived value
was 80 % of blood sampling radioactivity. Although
there was no statistically significant difference, theity (BS) and image-derived radioactivity (PET)
ry Left ventricle Right ventricle Inferior vena cava Abdominal aorta
83 ± 45 84 ± 32 80 ± 30 85 ± 47
78 ± 4 72 ± 4 92 ± 11 88 ± 15
81 ± 4 82 ± 3 102 ± 18 95 ± 9
67 ± 8 64 ± 8 82 ± 15 80 ± 10
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on the sampling time. In most of the blood pool, the
underestimation became larger. In contrast, the under-
estimation of the image-derived radioactivity in the in-
ferior vena cava and abdominal aorta were relatively
small as compared to other sites at 30 min after the
injection.
Table 2 showed a reduction rate per min (%/min) of
image-derived FBPA radioactivity in each blood pool
during the period between 30 to 50 min after injection.
The minimal reduction rate of image-derived blood
FBPA radioactivity was found in the left ventricle, but no
significant difference was found. Mean reduction rate of
blood sampling radioactivity was 0.95 ± 0.17 %/min.
In Table 3, the fraction of un-metabolized FBPA in
plasma at 20 min and 50 min after injection was shown
in each subject. Mean fraction of un-metabolized FBPA
at 20 min and 50 min was 97.68 ± 1.57 % and 96.03 ±
1.64 %, respectively.
Discussion
In the BNCT practice, the radioactivity of tumor (T) and
surrounding normal tissue (N) has been measured by
the FBPA PET, and the blood radioactivity (B) has been
measured by means of well-counter. The well-counter
radioactivity was usually converted to the PET count
using predetermined cross calibration factor (CCF). The
CCF is changeable depending on the performance of the
PET scanner and sensitivity of well-counter and one of
the source of errors for the accurate estimation of T/B
ratio and N/B ratio. Therefore, we assumed that the
radioactivity measurements for T, N, and B in the same
equipment will make the T/B and N/B estimation more
reliable and easier.
When the image-derived blood count of FBPA is
used for the calculation of T/B ratio, the radioactivity
in the tumor and that in the blood should be mea-
sured at the same time. However, when brain tumors
and head and neck tumors are studied, the time dis-
crepancy of PET measurement between the tumors
and blood pool in the chest is inevitable. In this situ-
ation, the blood radioactivity at the time of brain scan
and that at the time of body scan should be almost
equal. In the present study, the reduction of blood
radioactivity of FBPA after 30 min of injection was less
than 0.58 %/min, consistent with previous study [14].
Therefore, the PET imaging for tumor and blood pool
should be performed 30 min or later after injection in
order to minimize the discrepancy of the bloodTable 2 Comparison of the proportion of the reduction rate of imag
Ascending aorta Aortic arch Pulmonary artery
reduction rate (%)/min 1.32 ± 0.29 1.05 ± 0.30 1.37 ± 0.28
Data are mean ± SDradioactivity by the difference of scan time. The best
location of VOI setting was left ventricle because of
minimal reduction of blood FBPA counts.
The image-derived radioactivity measured in the left
ventricle and right ventricle 30 min after injection
showed high correlation (0.97 and 0.99, respectively),
slope close to be 1.0 (0.96 and 0.95, respectively), and
intercept (-161 and -149) with blood radioactivity. In
other blood pools and other timing at 30 min or later
after injection, either of correlation coefficient, slope or
intercept was not sufficient. In the aortic arch at 30 min
after injection, the correlation coefficient, slope, and
intercept was 0.98, 1.15, and -372, respectively. There-
fore, either left or right ventricle was appropriate for set-
ting VOI.
The present study indicated that image-derived blood
radioactivity underestimated blood-sampling radioactiv-
ity. When left ventricle and right ventricle were used for
the image-derived sampling, image-derived blood activ-
ity was 81 % and 82 % of blood sampling radioactivity,
respectively. Possible reasons for this underestimation
were partial volume effect due to the limited spatial
resolution of the current scanner, beat of the heart, and
respiratory movement [23]. Another inaccuracy of left
ventricular image-derived data might be due to spillover
of FBPA accumulated in the myocardium. As shown in
Fig. 2, however, physiological accumulation of FBPA in
the myocardium is low. In contrast, image-derived blood
counts in the inferior vena cava (102 %) and abdominal
aorta (95 %) were higher than those in other regions.
This might be due to the spillover from liver, kidney and
urinary system where physiological accumulation or ex-
cretion of FBPA were found [18].
10B concentration in the tumor during neutron irradi-
ation has been estimated by multiplying mean 10B con-
centration in the blood measured just before and after
irradiation by the T/B ratio of FBPA PET [4]. Since the
image-derived blood counts of FBPA were 81 % and
82 % of blood-sampling counts of left and right ventri-
cles, respectively, image-derived T/B ratio need a correc-
tion for the underestimation.
The present study showed that mean fraction of un-
metabolized FBPA in plasma at 20 min and 50 min after
injection was 97.68 % and 96.03 %, respectively. Imahori
et al. also reported negligibly small fraction of FBPA me-
tabolites in plasma and suggested no need of correction
for metabolites fraction [11]. It remained unknown
whether the FBPA metabolites were trapped by tumors
and normal tissues.e-derived radioactivity
Left ventricle Right ventricle Inferior vena cava Abdominal aorta
1.23 ± 0.30 1.37 ± 0.23 1.27 ± 0.27 1.13 ± 0.48
Table 3 FBPA metabolite measurements
Subject number The proportion of
unchanged FBPA
after 20 min (%)
The proportion of
unchanged FBPA






Isohashi et al. EJNMMI Research  (2016) 6:75 Page 7 of 8There were limitations of this study. Firstly, although
we collected blood samples for measuring the radioactiv-
ity levels during the scan, the blood sampling time was
not consistent with the scan time of each blood pool.
The blood sampling radioactivity measured to the near-
est time and the radioactivity of the blood pool on the
PET images were compared. Secondly, regarding the
underestimation of tumor radioactivity (T) due to the
partial volume effect of the current PET scanner, it has
been recommended to use maximal value of tumor
radioactivity within the voxel of interest. We expect the
improvement of spatial resolution and sensitivity of the
present PET scanner and the development of, appropri-
ate image reconstruction algorithm and image analysis
software may be better for spatial resolution and
sensitivity.Conclusions
Image-derived T/B ratios can be a substitute for blood
sampling-based T/B ratios. However, the value of image-
derived blood radioactivity represents an underestimate
in comparison with the value of blood sampling-based
blood radioactivity. The best location of VOI setting was
left ventricle because of minimal reduction of blood
FBPA counts. We conclude that the image-derived T/B
ratio can be reliably used by setting the VOI on the left
ventricle at 30 min after FBPA administration and cor-
recting for underestimation due to partial volume effect
and reduction of FBPA blood radioactivity.
Acknowledgments
The authors thank the staff of the Department of Nuclear Medicine, Osaka
University Hospital, for their assistance. This work was supported in part by
Grants-in-Aid for Scientific Research (S) (JP24229008) and for Scientific
Research (C) (JP24591758, JP15K09954) from the Ministry of Education,
Culture, Sports, Science and Technology, Japan.
Authors’ contributions
All authors participated in the design of the study. KI, ES, SN, YK, GH, IM and
KM performed the PET scans. KI, ES, TW, HK, and MT analyzed the images
and performed the statistical analysis. KI, ES and JH drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.Ethics approval and consent to participate
All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Author details
1Department of Nuclear Medicine and Tracer Kinetics, Osaka University
Graduate School of Medicine, 2-2, Yamadaoka, Suita City, Osaka 565-0871,
Japan. 2Department of Molecular Imaging in Medicine, Osaka University
Graduate School of Medicine, Suita City, Osaka, Japan. 3Department of
Radiology, Osaka University Graduate School of Medicine, Suita City, Osaka,
Japan. 4Department of Immunology Frontier Research Center, Osaka
University, Suita City, Osaka, Japan.
Received: 6 July 2016 Accepted: 4 October 2016
References
1. Barth RF, Soloway AH, Fairchild RG. Boron neutron capture therapy of
cancer. Cancer Res. 1990;50:1061–70.
2. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al.
Effectiveness of BNCT for recurrent head and neck malignancies. Appl
Radiat Isot. 2004;61:1069–73.
3. Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron
neutron capture therapy with bevacizumab may prolong the survival of
recurrent malignant glioma patients: four cases. Radiat Oncol. 2014.
doi:10.1186/1748-717X-9-6.
4. Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron
neutron capture therapy outcomes for advanced or recurrent head and
neck cancer. J Radiat Res. 2014;55:146–53.
5. Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al.
Treatment of malignant melanoma by single thermal neutron capture
therapy with melanoma-seeking 10B-compound. Lancet. 1989;2:388–9.
6. Hatanaka H, Nakagawa Y. Clinical results of long-surviving brain tumor
patients who underwent boron neutron capture therapy. Int J Radiat Oncol
Biol Phys. 1994;28:1061–6.
7. Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation
dosimetry of 4-borono-2-[18F] fluoro-D, L-phenylalanine: a target
compound for PET and boron neutron capture therapy. Int J Rad Appl
Instrum A. 1991;42:325–8.
8. Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, et al.
Predominant contribution of L-type amino acid transporter to 4-borono-2-
(18) F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med
Biol. 2013;40:625–9.
9. Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET
in boron neutron capture therapy for cancer: prediction of (10) B
concentration in the tumor and normal tissue in a rat xenograft model.
EJNMMI Res. 2014;4:70.
10. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron
emission tomography-based boron neutron capture therapy using
boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res.
1998;4:1833–41.
11. Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-
labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med.
1998;39:325–33.
12. Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First
clinical case of boron neutron capture therapy for head and neck
malignancies using 18F-BPA PET. Head Neck. 2006;28:850–5.
13. Ariyoshi Y, Shimahara M, Kimura Y, Ito Y, Shimahara T, Miyatake SI, et al.
Fluorine-18-labeled boronophenylalanine positron emission tomography for
oral cancers: Qualitative and quantitative analyses of malignant tumors and
normal structures in oral and maxillofacial regions. Oncol Lett. 2011;2:423–7.
14. Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al.
Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment
planning. J Nucl Med. 1997;38:1762–7.
15. Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, et al.
Modified boron neutron capture therapy for malignant gliomas performed
using epithermal neutron and two boron compounds with different
accumulation mechanisms: an efficacy study based on findings on
neuroimages. J Neurosurg. 2005;103:1000–9.
Isohashi et al. EJNMMI Research  (2016) 6:75 Page 8 of 816. Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al.
Effectiveness of boron neutron capture therapy for recurrent head and neck
malignancies. Appl Radiat Isot. 2009;67:S37–42.
17. Laramore GE, Spence AM. Boron neutron capture therapy (BNCT) for high-
grade gliomas of the brain: a cautionary note. Int J Radiat Oncol Biol Phys.
1996;36:241–6.
18. Lin YC, Hwang JJ, Wang SJ, Yang BH, Chang CW, Hsiao MC, et al. Macro-
and microdistributions of boron drug for boron neutron capture therapy in
an animal model. Anticancer Res. 2012;32:2657–64.
19. Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison
of radiation dosimetry of six PET tracers using human whole-body imaging
and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.
20. Ito H, Hatazawa J, Murakami M, Miura S, Iida H, Bloomfield PM, et al. Aging
effect on neutral amino acid transport at the blood-brain barrier measured
with L-[2-18F]-fluorophenylalanine and PET. J Nucl Med. 1995;36:1232–7.
21. Isohashi K, Shimosegawa E, Kato H, Kanai Y, Naka S, Fujino K, et al. Optimization
of [11C] methionine PET study: appropriate scan timing and effect of plasma
amino acid concentrations on the SUV. EJNMMI Res. 2013;3:27.
22. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S.
Estimation of absorbed doses in humans due to intravenous administration of
fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991;32:699–706.
23. De Geus-Oei LF, Visser EP, Krabbe PF, Van Hoorn BA, Koenders EB,
Willemsen AT, et al. Comparison of image-derived and arterial input
functions for estimating the rate of glucose metabolism in therapy-
monitoring 18F-FDG PET studies. J Nucl Med. 2006;47:945–9.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
